Recent News

• 10.24.2025 - MIRA Pharmaceuticals Initiates Multiple Ascending Dose (MAD) Phase 1 Study of Oral Ketamir-2 and Selects Chemotherapy-Induced Neuropathic Pain as Lead Phase 2a Indication
• 10.16.2025 - MIRA Pharmaceuticals Announces Oral Mira-55 Outperformed Injected Morphine in Normalizing Pain and Reducing Inflammation, Supporting Its Planned IND for Chronic Inflammatory Pain
• 09.30.2025 - MIRA Pharmaceuticals Closes Acquisition of SKNY Pharmaceuticals, Expands Pipeline with SKNY-1 for Obesity and Nicotine Addiction
• 09.22.2025 - MIRA Pharmaceuticals Announces Favorable Topline Results from Phase 1 SAD Study of Oral Ketamir-2, a Next-Generation Non-Scheduled Ketamine Analog
• 09.16.2025 - MIRA Pharmaceuticals Reports Positive PTSD Data Demonstrating Ketamir-2 Restores Normalized Behavior in Stressed Animals
• 09.12.2025 - MIRA Pharmaceuticals Shareholders Approve Acquisition of SKNY Pharmaceuticals, Advancing Next-Generation Oral Therapeutic for Obesity and Smoking Cessation
• 08.19.2025 - MIRA Pharmaceuticals Announces Completion of Phase 1 Single Ascending Dose for Oral Ketamir-2 with No Safety Concerns, Advances to Multiple Ascending Dose Stage

Recent Filings

• 10.23.2025 - 8-K Current report
• 10.16.2025 - 8-K Current report
• 10.15.2025 - 8-K Current report
• 10.03.2025 - 4 Statement of changes in beneficial ownership of securities
• 10.03.2025 - 3 Initial statement of beneficial ownership of securities
• 10.03.2025 - 4 Statement of changes in beneficial ownership of securities
• 09.30.2025 - 8-K Current report
• 09.22.2025 - 8-K Current report
• 09.18.2025 - 4 Statement of changes in beneficial ownership of securities
• 09.15.2025 - 8-K Current report